Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Mineralys Therapeutics Price Performance
Shares of MLYS stock traded up $0.11 on Tuesday, hitting $13.70. 65,103 shares of the stock traded hands, compared to its average volume of 176,427. Mineralys Therapeutics, Inc. has a 1-year low of $5.85 and a 1-year high of $16.91. The company’s fifty day moving average is $11.89 and its 200 day moving average is $12.42. The company has a market capitalization of $680.19 million, a PE ratio of -6.26 and a beta of 1.93.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter last year, the company earned ($0.31) earnings per share. As a group, equities research analysts expect that Mineralys Therapeutics, Inc. will post -3.08 EPS for the current year.
Hedge Funds Weigh In On Mineralys Therapeutics
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Thursday, August 15th.
View Our Latest Report on MLYS
Mineralys Therapeutics Company Profile
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Featured Stories
- Five stocks we like better than Mineralys Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- AMD Gains Momentum With AI: Can It Beat Expectations?
- How to Capture the Benefits of Dividend Increases
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.